Ensysce Biosciences, Inc. ENSC
We take great care to ensure that the data presented and summarized in this overview for Ensysce Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENSC
View allLatest Institutional Activity in ENSC
Top Purchases
Top Sells
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Insider Transactions at ENSC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Bob G Gower Director |
BUY
Open market or private purchase
|
Direct |
90,287
+6.88%
|
$0
$0.49 P/Share
|
|
Mar 01
2023
|
Bob G Gower Director |
BUY
Open market or private purchase
|
Direct |
270,000
+19.25%
|
$0
$0.48 P/Share
|
|
Feb 28
2023
|
Bob G Gower Director |
BUY
Open market or private purchase
|
Direct |
109,300
+11.25%
|
$0
$0.49 P/Share
|
|
Dec 09
2022
|
Bob G Gower Director |
BUY
Open market or private purchase
|
Direct |
357,143
+32.17%
|
$357,143
$1.4 P/Share
|
|
May 26
2022
|
Lynn Kirkpatrick Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
27,000
+6.6%
|
$0
$0.53 P/Share
|
|
May 25
2022
|
Lynn Kirkpatrick Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
70,000
+16.48%
|
$0
$0.49 P/Share
|
|
Jun 30
2021
|
Lynn Kirkpatrick Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
284,851
+50.0%
|
-
|
|
Jun 30
2021
|
Bob G Gower Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,919,026
+50.0%
|
-
|
|
Jun 30
2021
|
William H Chang Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,242,189
+50.0%
|
-
|
|
Jun 30
2021
|
William H Chang Director |
BUY
Grant, award, or other acquisition
|
Direct |
353,451
+50.0%
|
-
|
|
Jun 30
2021
|
David Carl Humphrey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jan 15
2018
|
Hg Vora Capital Management, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
375,000
-9.77%
|
-
|
|
Dec 05
2017
|
Hg Vora Capital Management, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
718,750
-20.21%
|
-
|
|
Dec 01
2017
|
Hg Vora Capital Management, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+20.67%
|
$10,000,000
$10.0 P/Share
|